While China s another 9 vaccines are only in the first or second phase of human trials, the data says another 17 vaccines from different parts of the world are in the final Phase III stage, which means these vaccines are likely to be available commercially in the coming months. Prominent among them are Zycov-D from India s Zydus Cadila which is expected to be launched in the coming months and Hyderabad-based manufacturer Biological E s BECOV2, which got final phase trial clearance from the Drug Controller General of India (DCGI) last week. Serum Institute, in partnership with US-based Novavax is planning to launch a vaccine by September and its entire production and development was supported by Serum. The vaccine will be manufactured in Pune and at a facility serum sold to Novovax in Europe.